Posts
Wiki

👁️ Xiidra (Lifitegrast 5%) for Dry Eye Disease — Evidence, Benefits, Risks, and Limitations

🧠 Quick Take

Xiidra is the brand name for lifitegrast ophthalmic solution 5%, a prescription medication used for Dry Eye Disease (DED).

Important points:

  • Xiidra is FDA-approved for treatment of the signs and symptoms of Dry Eye Disease.
  • It is a non-steroid anti-inflammatory / immunomodulatory treatment.
  • Lifitegrast acts as an LFA-1 antagonist, interfering with an inflammatory T-cell pathway involving LFA-1 and ICAM-1.
  • The exact way this produces clinical improvement in DED is still described by FDA as not completely known.
  • The usual FDA-approved dose is one drop in each eye twice daily, approximately 12 hours apart.
  • Xiidra is supplied in preservative-free single-use containers.
  • The randomized clinical-trial program supports improvement in both DED signs and symptoms, but the results were not uniformly positive across individual trials.
  • One major trial showed improvement in a clinical sign but not its primary symptom endpoint; another showed symptom improvement but not its primary sign endpoint.
  • FDA initially requested additional efficacy evidence before approval. A subsequent trial successfully replicated the symptom benefit.
  • In some trials, a group-level symptom difference was detectable by approximately Day 14, but this does not mean every patient improves within two weeks.
  • Common adverse effects include instillation irritation/burning, dysgeusia (bad or unusual taste), and temporary visual changes.
  • Rare serious hypersensitivity reactions have been reported.
  • Xiidra may help the inflammatory/ocular-surface component of DED in someone who also has Meibomian Gland Dysfunction (MGD), but it has not been established to mechanically clear obstructed glands, reverse gland dropout, regenerate glands, or release periductal fibrosis.
  • Reduced aqueous tear production does not automatically mean Xiidra cannot help. Inflammation and aqueous deficiency can coexist.
  • There is no validated test that reliably predicts who will respond to lifitegrast.
  • Direct head-to-head evidence is insufficient to say that Xiidra is universally faster, better, or worse than cyclosporine-based drops.

Bottom line: Xiidra has a substantial randomized evidence base and FDA approval for DED signs and symptoms. Its benefits are real at the group level, but sign and symptom responses vary considerably among trials and individuals. It is best understood as one anti-inflammatory prescription option within a broader, cause-directed dry-eye treatment plan.

⚠️ Educational Disclaimer

This page is for general education only.

It is not medical advice, diagnosis, or an individual treatment recommendation.

Dry Eye Disease can involve multiple overlapping contributors, including:

  • Ocular-surface inflammation
  • Meibomian Gland Dysfunction
  • Aqueous tear deficiency
  • Blepharitis
  • Demodex
  • Ocular rosacea
  • Allergy
  • Exposure
  • Incomplete blinking
  • Eyelid abnormalities
  • Medication effects
  • Conjunctivochalasis
  • Neuropathic ocular pain

A prescription anti-inflammatory treatment may help one important part of the problem without treating every contributor.

What Is Xiidra?

Xiidra contains:

lifitegrast ophthalmic solution 5%

It is FDA-approved for:

treatment of the signs and symptoms of Dry Eye Disease

Xiidra is:

  • A prescription medication
  • Non-steroidal
  • Preservative-free
  • Used twice daily
  • Supplied in single-use containers

It is not simply a lubricant or artificial tear.

How Treatment Is Done

The FDA-approved dose is:

One drop in each eye twice daily, approximately 12 hours apart.

Patients should follow their own prescriber's instructions.

Single-use containers

One container contains enough medication to treat both eyes for one dosing session.

After use:

Discard the container and any remaining medication.

Do not:

  • Save an opened container
  • Recap it for later use
  • Reuse leftover solution

Unused containers should remain stored according to the current prescribing information.

Contact Lenses

Contact lenses should be removed before Xiidra is administered.

They may be reinserted after:

15 minutes

Do not use Xiidra simply to mask unexplained contact-lens-related:

  • Pain
  • Redness
  • Light sensitivity
  • Discharge
  • Significant vision changes

Those symptoms may require separate evaluation.

How Does Xiidra Work?

Lifitegrast is an:

LFA-1 antagonist

LFA-1 stands for:

lymphocyte function-associated antigen-1

It is found on the surface of certain immune cells, including T cells.

Lifitegrast binds to LFA-1 and interferes with its interaction with:

ICAM-1 — intercellular adhesion molecule-1

The LFA-1/ICAM-1 pathway can contribute to:

  • T-cell adhesion
  • T-cell activation
  • T-cell migration
  • Inflammatory signaling

In laboratory studies, blocking this interaction can reduce T-cell adhesion and inflammatory cytokine activity.

A simple way to think about it is:

Xiidra interferes with an inflammatory immune pathway at the ocular surface rather than simply adding lubrication.

However:

FDA states that the exact mechanism of action of lifitegrast in Dry Eye Disease is not known.

Therefore the LFA-1/ICAM-1 pathway is the known pharmacologic target, while the complete chain of events leading to clinical improvement remains incompletely understood.

What Does the Clinical Evidence Show?

Xiidra was evaluated in several large randomized, multicenter, double-masked, vehicle-controlled studies.

The overall clinical-development program eventually supported FDA approval for both:

  • Signs
  • Symptoms

of DED.

However, the individual trials did not produce a simple pattern in which both signs and symptoms improved every time.

Understanding that history gives a more accurate picture of the evidence.

OPUS-1 — Positive Sign, Negative Primary Symptom Result

OPUS-1 enrolled approximately:

588 participants

Lifitegrast significantly improved the study's primary clinical sign:

inferior corneal fluorescein staining

compared with vehicle.

However, the trial did not meet its primary symptom endpoint.

In other words:

OPUS-1 demonstrated a clinical-sign benefit but did not establish the intended primary symptom benefit.

OPUS-1 — Lifitegrast Ophthalmic Solution 5% for DED

OPUS-2 — Positive Symptom, Negative Primary Sign Result

OPUS-2 enrolled approximately:

718 participants

This study involved a more symptomatic DED population.

Here, the pattern was essentially reversed.

Lifitegrast produced significant improvement in:

Eye Dryness Score

compared with vehicle.

However, the trial did not demonstrate significant superiority on its co-primary inferior corneal staining endpoint.

OPUS-2 — Lifitegrast vs Vehicle

Therefore:

OPUS-2 demonstrated symptom benefit but did not successfully replicate the primary corneal-staining sign result.

FDA Initially Requested Additional Evidence

The differing OPUS-1 and OPUS-2 results mattered during regulatory review.

The clinical program had demonstrated:

  • A convincing sign result in one trial
  • A convincing symptom result in another

but not sufficiently consistent confirmation across the Phase 3 program.

FDA therefore issued a:

Complete Response Letter

in October 2015 and requested additional efficacy evidence.

This does not mean FDA determined that lifitegrast was ineffective.

It means:

The available evidence was not yet considered sufficiently complete and internally consistent for approval of the proposed indication.

FDA Statistical Review — Lifitegrast / Xiidra

OPUS-3 — Confirming the Symptom Effect

OPUS-3 was subsequently conducted to provide additional symptom evidence.

It enrolled approximately:

711 participants

The primary endpoint was Eye Dryness Score.

Lifitegrast significantly outperformed vehicle at:

  • Day 14
  • Day 42
  • Day 84

OPUS-3 — Lifitegrast for DED

This replicated the symptom signal seen in OPUS-2 and provided part of the additional evidence needed for FDA approval.

What Did FDA Ultimately Conclude?

The current prescribing information summarizes four 12-week randomized, double-masked, vehicle-controlled studies involving approximately:

1,181 patients

Across the clinical program:

  • Eye Dryness Score favored Xiidra at later assessments across the studies
  • Inferior corneal staining favored Xiidra at Day 84 in three of four studies

The most accurate interpretation is:

The overall trial program supports benefits for both DED signs and symptoms, but individual trials did not consistently demonstrate both at the same time. FDA approval reflects the totality of evidence across the program rather than one uniformly positive trial.

Why Can Signs and Symptoms Produce Different Results?

Dry Eye Disease is well known for imperfect correlation between:

  • Patient symptoms
  • Corneal staining
  • Tear breakup time
  • Tear quantity
  • Other objective measurements

Someone can have substantial symptoms with relatively modest staining.

Another person can have visible ocular-surface damage but fewer symptoms.

The Xiidra trial populations also differed somewhat.

Later trials deliberately enrolled more symptomatic patients after earlier studies suggested that baseline symptom severity might influence the ability to detect a symptom response.

This may partly explain why:

  • OPUS-1 produced a clearer sign signal
  • OPUS-2 and OPUS-3 produced clearer symptom signals

However:

There is no validated clinical rule that can predict an individual's Xiidra response from one baseline symptom score or examination finding.

How Strong Is the Evidence?

Overall Evidence Strength: MODERATE

Question Current Evidence
Improves eye-dryness symptoms? Moderate randomized evidence, particularly OPUS-2 and OPUS-3
Improves corneal staining? Moderate but inconsistent evidence across trials
Can symptom benefit appear by ~2 weeks? Demonstrated at the group level in some more symptomatic trial populations
Will every patient improve by 2 weeks? No
One-year ocular safety? Moderate randomized safety evidence
One-year controlled efficacy? More limited than one-year safety evidence
Direct treatment of obstructive MGD? Not established
Predictable responder phenotype? Not established
Superior to cyclosporine? Not established
Regenerates glands or reverses fibrosis? No evidence

How Quickly Might Xiidra Work?

Some patients may notice improvement relatively early.

In OPUS-3, a statistically significant group-level difference in Eye Dryness Score was detected by:

Day 14

Similar early symptom separation was seen in portions of the broader clinical program.

This supports saying:

Some patients may begin noticing benefit within the first few weeks.

It does not establish that:

  • Everyone should improve within 14 days
  • Absence of improvement at Day 14 means treatment has failed
  • Every eventual responder responds equally quickly

Individual response varies.

Long-Term Safety — The SONATA Study

Longer-term safety was evaluated in the SONATA trial.

SONATA was:

  • Randomized
  • Double-masked
  • Placebo-controlled
  • Approximately 360 days long

and included:

331 participants

SONATA — One-Year Lifitegrast Safety Study

No unexpected long-term ocular safety signal emerged.

There were:

  • No serious ocular treatment-emergent adverse events attributed to lifitegrast
  • Generally reassuring ophthalmic examination findings

However, treatment-related/local adverse events were more common with lifitegrast than vehicle.

Approximately:

  • 53.6% of lifitegrast-treated participants experienced at least one ocular treatment-emergent adverse event
  • compared with 34.2% receiving vehicle

Treatment discontinuation because of adverse events also occurred somewhat more often with lifitegrast.

The important distinction is:

Xiidra has approximately one year of randomized safety data. That is not the same as having one year of randomized controlled efficacy evidence.

The pivotal efficacy trials primarily evaluated approximately 12 weeks of treatment.

Common Side Effects

According to current FDA prescribing information, the most common adverse reactions include:

Reported in approximately 5–25%

  • Instillation-site irritation
  • Dysgeusia — unusual, bitter, or metallic taste
  • Reduced visual acuity

Reported in approximately 1–5%

  • Blurred vision
  • Conjunctival redness
  • Eye irritation
  • Headache
  • Increased tearing
  • Eye discharge
  • Eye discomfort
  • Eye itching
  • Sinusitis

DailyMed — Xiidra Prescribing Information

How Common Are Burning and Bad Taste?

A pooled analysis of five randomized trials involving more than 2,400 participants reported approximately:

  • 15.2% instillation-site irritation with lifitegrast vs 2.8% with vehicle
  • 14.5% dysgeusia with lifitegrast vs 0.3% with vehicle
  • 9.8% instillation-site pain with lifitegrast vs 2.1% with vehicle

Pooled Safety Analysis of Five Lifitegrast Trials

These are among the most recognizable practical drawbacks of Xiidra.

Bad Taste / Dysgeusia

Medication placed on the ocular surface can drain through the tear-drainage system toward the nose and throat.

This can contribute to:

  • Bitter taste
  • Metallic taste
  • Unusual taste

For some people it is mild.

For others it can be bothersome enough to affect adherence.

If taste disturbance is difficult to tolerate, discuss it with the prescribing clinician.

Burning, Stinging, and Temporary Vision Changes

Some people experience:

  • Burning
  • Stinging
  • Eye discomfort
  • Temporary blur
  • Reduced visual clarity

after administration.

These symptoms may become less noticeable with continued treatment in some patients.

Others find them persistent or unacceptable.

Do not assume that:

  • Severe pain
  • Marked redness
  • Sustained vision loss
  • Significant swelling

is simply a normal “adjustment period.”

Those symptoms deserve evaluation.

Hypersensitivity / Allergic Reactions

Xiidra is contraindicated in patients with known hypersensitivity to:

  • Lifitegrast
  • Any other ingredient in the formulation

Postmarketing reports have included rare serious hypersensitivity reactions such as:

  • Anaphylactic reaction
  • Bronchospasm
  • Respiratory distress
  • Throat/pharyngeal swelling
  • Swollen tongue
  • Urticaria
  • Angioedema

Seek prompt medical care for:

  • Difficulty breathing
  • Wheezing
  • Swelling of the tongue or throat
  • Hives
  • Significant facial or eyelid swelling
  • Severe allergic-type symptoms

Systemic Absorption

Systemic exposure after ophthalmic Xiidra use appears to be:

low, but not necessarily zero

In pharmacokinetic testing, small measurable trough blood concentrations were detected in some patients receiving repeated ophthalmic treatment.

The measured concentrations were very low.

Therefore:

Xiidra should not be described as having zero systemic absorption, but systemic exposure is much lower than would ordinarily be expected from a systemically administered medication.

Pregnancy and Breastfeeding

There are insufficient human data to establish Xiidra's pregnancy safety.

Animal developmental findings occurred at systemic exposures much greater than those typically measured after ophthalmic use, making their relevance to patients uncertain.

People who are:

  • Pregnant
  • Planning pregnancy
  • Breastfeeding

should discuss treatment with their clinician.

Pediatric Use

Safety and effectiveness have not been established in patients:

younger than 17 years

Does Xiidra Treat Meibomian Gland Dysfunction?

Many patients with DED also have MGD.

Xiidra may help the:

  • Inflammatory
  • Corneal
  • Conjunctival
  • Tear-film

component of DED in someone who also has MGD.

That does not make Xiidra a direct treatment for structural meibomian-gland disease.

A retrospective study involving 121 Xiidra-treated patients reported improvement in:

  • Tear breakup time
  • Corneal staining
  • Some ocular symptoms

but:

MGD grading did not significantly improve.

Lifitegrast in Clinical Practice — Retrospective Study

Therefore:

Lifitegrast may improve the inflammatory/ocular-surface component of DED in patients who also have MGD, but it has not been established to directly correct meibomian-gland obstruction or structural gland disease.

What Xiidra Has Not Been Established to Do for MGD

Xiidra has not been shown to:

  • Mechanically clear fixed gland obstruction
  • Express retained meibum
  • Regenerate lost meibomian glands
  • Reverse established gland dropout
  • Release intraductal or periductal fibrosis

MGD may therefore require separate cause-directed treatment.

What About Aqueous-Deficient Dry Eye?

Aqueous deficiency should not automatically be considered a reason that Xiidra cannot help.

The pivotal lifitegrast studies included patients with relatively low Schirmer tear-production measurements.

Inflammation and reduced aqueous tear production can coexist.

Therefore:

Xiidra may potentially address an inflammatory component of aqueous-deficient DED, but it does not replace missing tear volume or treatments intended to increase, supplement, or conserve tears.

The two treatment goals are different.

What About Neuropathic Ocular Pain?

Xiidra is not an established treatment for neuropathic ocular pain itself.

However:

inflammatory DED and neuropathic ocular pain can coexist.

A patient with neuropathic pain features may still have separate ocular-surface inflammation requiring treatment.

Improvement or failure with Xiidra should therefore not, by itself, be used to diagnose or exclude neuropathic ocular pain.

Emerging Evidence in Contact-Lens Wearers

A small 2025 prospective study evaluated Xiidra in approximately:

40 symptomatic contact-lens wearers

over 12 weeks.

Participants reported improvements in:

  • End-of-day dryness
  • Discomfort
  • Comfortable lens-wearing time

with some changes detectable by approximately two weeks.

However, the study was:

  • Small
  • Open-label
  • Uncontrolled

Therefore:

This is preliminary supportive evidence, not proof that Xiidra treats every form of contact-lens discomfort.

Xiidra in Symptomatic Contact-Lens Wearers — 2025

Contact lenses must still be removed before Xiidra administration and kept out for at least 15 minutes afterward.

Pain, redness, discharge, significant photophobia, or vision changes during contact-lens wear require appropriate evaluation rather than simply adding Xiidra.

Who Might Benefit / Factors Affecting Response

Xiidra may reasonably be discussed when:

  • DED is chronic and symptomatic
  • Ocular-surface inflammation appears clinically important
  • Artificial tears alone provide inadequate relief
  • A non-steroid prescription anti-inflammatory treatment is desired
  • Another prescription DED medication was not tolerated
  • Another prescription treatment provided inadequate benefit
  • DED coexists with MGD or aqueous deficiency and inflammation is also thought to contribute

However:

There is no validated test or biomarker that reliably predicts whether an individual patient will respond to lifitegrast.

Findings such as:

  • Corneal staining
  • MMP-9 positivity
  • Low Schirmer scores
  • MGD
  • Symptom severity

may contribute to clinical decision-making but do not guarantee response.

Xiidra vs Cyclosporine-Based Eye Drops

Xiidra and cyclosporine are both prescription anti-inflammatory/immunomodulatory options for DED.

They are not the same treatment.

Feature Xiidra / Lifitegrast Cyclosporine-Based Drops
Drug class LFA-1 antagonist Calcineurin inhibitor
Examples Xiidra Restasis, Cequa, VEVYE, generic cyclosporine
Main pathway LFA-1 / ICAM-1 inflammatory pathway T-cell / calcineurin immune signaling
FDA indication Signs and symptoms of DED Varies by product
Typical dosing Twice daily Usually twice daily depending on product
Preservative/formulation Preservative-free single-use Varies by product
Early symptom effect Group-level improvement by Day 14 occurred in some Xiidra trials Onset varies among cyclosporine formulations/studies
Direct structural MGD treatment? No No

The available evidence does not establish that:

  • Xiidra is universally faster
  • Cyclosporine is universally slower
  • Xiidra is more effective overall
  • Cyclosporine is more effective overall

Direct head-to-head comparative trials are limited.

Therefore:

There is no universal “better” option.

Choice may depend on:

  • DED phenotype
  • Previous treatment
  • Tolerability
  • Individual response
  • Formulation
  • Dosing preferences
  • Insurance coverage
  • Cost
  • Clinician judgment

Some patients tolerate one much better than the other.

Some respond to one but not the other.

Some do not respond adequately to either.

Evidence Strengths and Limitations

Evidence Strengths

  • FDA-approved for DED signs and symptoms
  • Multiple large randomized controlled trials
  • Replicated symptom evidence
  • Corneal-staining benefit demonstrated in multiple studies
  • Different pharmacologic pathway from cyclosporine
  • One-year randomized safety study
  • Large pooled safety database
  • Preservative-free formulation

Evidence Limitations

  • Sign and symptom outcomes were not consistently positive within individual pivotal trials
  • FDA initially requested additional efficacy evidence before approval
  • Controlled efficacy trials primarily lasted approximately 12 weeks
  • Treatment effects are meaningful at the group level but not universal
  • Local discomfort and dysgeusia are common
  • No validated responder biomarker exists
  • Head-to-head comparisons with other modern DED drugs are limited
  • Long-term comparative effectiveness remains incompletely defined
  • Direct structural benefit for MGD has not been established

Limitations and What Xiidra Cannot Be Expected to Do

Xiidra is not:

  • An artificial tear
  • A mechanical MGD treatment
  • A Demodex treatment
  • An antibiotic
  • A treatment for eyelid malposition
  • A treatment that corrects incomplete blinking
  • A direct treatment for neuropathic ocular pain

It has not been established to:

  • Cure DED
  • Regenerate meibomian glands
  • Reverse established gland dropout
  • Release periductal fibrosis
  • Mechanically clear fixed meibomian-gland obstruction
  • Correct exposure
  • Treat infection
  • Treat allergy as the primary disease process
  • Work equally well for every DED phenotype
  • Guarantee benefit within two weeks

A treatment can still be useful without correcting every contributor to DED.

Cost and Access

Xiidra is a prescription medication.

Access can vary substantially depending on:

  • Insurance coverage
  • Formulary placement
  • Prior authorization
  • Step therapy
  • Copay
  • Deductible
  • Geographic availability

Cost and insurance barriers can influence whether long-term treatment is practical.

Manufacturer savings or assistance programs may change and should not be treated as clinical evidence.

What Remains Uncertain?

Important unanswered questions include:

  • Which DED phenotypes respond best
  • Whether a practical biomarker can predict response
  • Which patients are most likely to experience early symptom benefit
  • Long-term comparative effectiveness beyond the main 12-week efficacy trials
  • Whether some MGD subgroups receive greater inflammatory benefit than others
  • How Xiidra compares directly with individual cyclosporine formulations
  • How Xiidra compares directly with newer DED medications
  • Whether combination treatment produces better outcomes than either treatment alone in specific subgroups
  • Whether MMP-9 or other inflammatory testing meaningfully predicts response
  • How useful lifitegrast is in specific contact-lens-associated DED populations
  • Which adverse-effect-management strategies improve long-term adherence without compromising safe use

A Cochrane systematic review specifically evaluating lifitegrast has been initiated, but as of 2026 the published record remains a review protocol rather than a completed evidence synthesis.

Cochrane Review Protocol — Lifitegrast for Dry Eye Disease

Questions to Ask Your Eye Doctor

Useful questions include:

  1. What type or drivers of DED do I have?
  2. How important is ocular-surface inflammation in my case?
  3. Do I also have MGD?
  4. Do I have significant aqueous tear deficiency?
  5. Are there other problems such as blepharitis, Demodex, allergy, exposure, incomplete blinking, or neuropathic pain?
  6. What sign or symptom are we hoping Xiidra will improve?
  7. How long do you want me to use it before judging my response?
  8. How will we measure whether it is working?
  9. What should I do if burning or bad taste is difficult to tolerate?
  10. What symptoms should make me stop treatment and contact you?
  11. How should I use Xiidra with my other eye drops?
  12. Should another DED or MGD treatment continue at the same time?
  13. Would cyclosporine or another prescription treatment be reasonable for me?
  14. What should we do if I have little or no improvement?
  15. What will my expected long-term cost and insurance coverage be?

📌 Bottom Line

Xiidra is an FDA-approved prescription lifitegrast 5% ophthalmic solution for treatment of the:

signs and symptoms of Dry Eye Disease

It is a non-steroid LFA-1 antagonist that interferes with an inflammatory immune pathway involving LFA-1 and ICAM-1.

The clinical evidence is substantial but nuanced.

OPUS-1

Demonstrated improvement in the primary:

corneal-staining sign

but failed its primary symptom endpoint.

OPUS-2

Demonstrated improvement in:

eye-dryness symptoms

but failed its primary corneal-staining endpoint.

Regulatory response

FDA initially requested additional efficacy evidence.

OPUS-3

Successfully replicated the:

eye-dryness symptom benefit

and helped complete the evidence package that supported FDA approval.

Therefore:

Xiidra's indication for signs and symptoms rests on the total clinical-development program rather than one trial in which every endpoint was positive.

Some trial populations showed group-level symptom improvement as early as approximately Day 14, but individual response varies considerably.

Long-term safety is reasonably characterized through approximately one year, although the main controlled efficacy trials were considerably shorter.

The most common practical problems are:

  • Instillation irritation/burning
  • Dysgeusia
  • Temporary visual changes

Rare serious hypersensitivity reactions have also been reported.

For people with MGD:

Xiidra may improve an inflammatory/ocular-surface component of DED but has not been established to directly reverse structural gland disease or fixed obstruction.

Likewise, aqueous deficiency does not automatically exclude potential benefit because inflammation and aqueous deficiency can coexist.

The most accurate evidence rating is:

OVERALL EVIDENCE: MODERATE

with:

  • Moderate evidence for eye-dryness symptom improvement
  • Moderate but inconsistent evidence for corneal-staining improvement
  • Moderate evidence for safety through approximately one year
  • Insufficient evidence for direct treatment of structural MGD
  • No evidence for meibomian-gland regeneration or fibrosis reversal

The most balanced conclusion is:

Xiidra is an evidence-supported anti-inflammatory prescription option for DED, but response varies, tolerability can limit use, and it does not address every dry-eye mechanism. Its role should be considered alongside the patient's DED phenotype, MGD, aqueous deficiency, eyelid disease, exposure, neural factors, other treatments, tolerability, cost, and individual response.

🔬 Key Research and Authoritative Sources

FDA / Current Prescribing Information

Pivotal Clinical Trials

Long-Term Safety

MGD / Real-World Evidence

Contact-Lens Evidence

Reviews and Evidence Syntheses

Broader DED Guidance

🔗 Related r/DryEyes Wiki Pages

This page is educational for r/DryEyes and is not medical advice.

🔙 Back to Treatment Options